风湿科医生能否明确诊断病程不足2年的慢性背痛患者的轴性脊柱关节炎?SPACE队列2年主要结局
SPACE队列纳入552例病程≤2年、病因不明的慢性背痛患者(<45岁),在基线、3个月、1年和2年时由风湿科医生以信心水平(LoC≥7)诊断轴性脊柱关节炎(axSpA)。基线时32%诊断为明确axSpA(d-axSpA),2年时为30%;基线诊断在2年时5%被修正、8%新获得d-axSpA,30%仍存在诊断不确定性。HLA-B27阳性和基线骶髂关节炎影像最能区分2年时d-axSpA与d-非axSpA患者。
要点
- 552例慢性背痛患者中,基线d-axSpA为175例(32%),2年时为165例(30%)。
- 2年时基线d-axSpA仅5%被修正,8%新获得d-axSpA,30%诊断不确定性持续。
- HLA-B27阳性和基线骶髂关节炎影像最能区分2年时d-axSpA与d-非axSpA。
核心结论
- 近三分之一转诊风湿科的慢性背痛患者可可靠地诊断为d-axSpA。
- 2年后诊断不确定性可能仍存在于5%至30%的患者中。
- 重复评估的收益有限,但对男性HLA-B27阳性患者重复MRI可能值得。
研究设计与样本
- SPACE是一项欧洲队列研究,分析2年数据。
- 纳入年龄<45岁、慢性背痛≥3个月且≤2年、病因不明的患者552例。
- 诊断评估包括临床SpA特征、急性期反应物、HLA-B27、X线和MRI(骶髂关节和脊柱),并重复评估。
- 每次访视(基线、3个月、1年、2年)由风湿科医生报告axSpA或非axSpA诊断及信心水平(LoC,0为完全无信心至10为非常有信心)。
- 主要结局为2年时LoC≥7的axSpA诊断(d-axSpA)。
主要发现
- 552例慢性背痛患者中,基线d-axSpA为175例(32%),2年时为165例(30%)。
- 2年时基线d-axSpA在5%的患者中被修正,8%的患者新获得d-axSpA。
- 诊断不确定性在30%的患者中持续存在。
- HLA-B27阳性和基线骶髂关节炎影像最能区分2年时d-axSpA与2年时d-非axSpA患者。
- 新发d-axSpA诊断的患者随访中最常出现NSAIDs良好反应和MRI骶髂关节炎;发生MRI骶髂关节炎的8例中7例HLA-B27阳性、5例为男性。
关键数值与推荐
- d-axSpA定义为风湿科医生axSpA诊断且信心水平LoC≥7(0为完全无信心至10为非常有信心)。
- 慢性背痛定义为≥3个月且≤2年、病因不明。
- 患者年龄<45岁。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the prevalence of axial spondyloarthritis (axSpA) in patients with chronic back pain (CBP) of less than 2 years (2y) duration referred to the rheumatologist, the development of diagnosis over time, and patient characteristics of those developing definite (d-)axSpA over 2y. METHODS: We analysed the 2y data from SPondyloArthritis Caught Early, a European cohort of patients (<45 years) with CBP (≥3 months, ≤2y) of unknown origin. The diagnostic workup comprised evaluation of clinical SpA features, acute phase reactants, HLA-B27, radiographs and MRI (sacroiliac joints and spine), with repeated assessments. At each visit (baseline, 3 months, 1y and 2y), rheumatologists reported a diagnosis of axSpA or non-axSpA with level of confidence (LoC; 0-not confident at all to 10-very confident). MAIN OUTCOME: axSpA diagnosis with LoC≥7 (d-axSpA) at 2y. RESULTS: In 552 patients with CBP, d-axSpA was diagnosed in 175 (32%) at baseline and 165 (30%) at 2y. Baseline diagnosis remained rather stable: at 2y, baseline d-axSpA was revised in 5% of patients, while 8% 'gained' d-axSpA. Diagnostic uncertainty persisted in 30%. HLA-B27+ and baseline sacroiliitis imaging discriminated best 2y-d-axSpA versus 2y-d-non-axSpA patients. Good response to non-steroidal anti-inflammatory drugs and MRI-sacroiliitis most frequently developed over follow-up in patients with a new d-axSpA diagnosis. Of the patients who developed MRI-sacroiliitis, 7/8 were HLA-B27+ and 5/8 male. CONCLUSION: A diagnosis of d-axSpA can be reliably made in nearly one-third of patients with CBP referred to the rheumatologist, but diagnostic uncertainty may persist in 5%-30% after 2y. Repeated assessments yield is modest, but repeating MRI may be worthwhile in male HLA-B27+ patients.
引用
- Marques ML, Ramiro S, van Lunteren M, et al. Can rheumatologists unequivocally diagnose axial spondyloarthritis in patients with chronic back pain of less than 2 years duration? Primary outcome of the 2-year SPondyloArthritis Caught Early (SPACE) cohort. Ann Rheum Dis. 2024. PMID: 38233104. doi:10.1136/ard-2023-224959
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。